Institutional Repository of Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing 100190, Peoples R China
Selection Between Liver Resection Versus Transarterial Chemoembolization in Hepatocellular Carcinoma: A Multicenter Study | |
Fu, Sirui1,2; Wei, Jingwei2,3![]() ![]() ![]() ![]() | |
发表期刊 | CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
![]() |
ISSN | 2155-384X |
2019-08-01 | |
卷号 | 10页码:12 |
通讯作者 | Tian, Jie(tian@ieee.org) ; Lu, Ligong(llg0902@sina.com) |
摘要 | OBJECTIVES: Models should be developed to assist choice between liver resection (LR) and transarterial chemoembolization (TACE) for hepatocellular carcinoma. METHODS: After separating 520 cases from 5 hospitals into training (n = 302) and validation (n = 218) data sets, we weighted the cases to control baseline difference and ensured the causal effect between treatments (LR and TACE) and estimated progression-free survival (PFS) difference. A noninvasive PFS model was constructed with clinical factors, radiological characteristics, and radiomic features. We compared our model with other 4 state-of-the-art models. Finally, patients were classified into subgroups with and without significant PFS difference between treatments. RESULTS: Our model included treatments, age, sex, modified Barcelona Clinic Liver Cancer stage, fusion lesions, hepatocellular carcinoma capsule, and 3 radiomic features, with good discrimination and calibrations (area under the curve for 3-year PFS was 0.80 in the training data set and 0.75 in the validation data set; similar results were achieved in 1- and 2-year PFS). The model had better accuracy than the other 4 models. A nomogram was built, with different scores assigned for LR and TACE. Separated by the threshold of score difference between treatments, for some patients, LR provided longer PFS and might be the better option (training: hazard ratio [HR] = 0.50, P= 0.014; validation: HR = 0.52, P= 0.026); in the others, LR provided similar PFS with TACE (training: HR = 0.84, P = 0.388; validation: HR = 1.14, P = 0.614). TACE may be better because it was less invasive. DISCUSSION: We propose an individualized model predicting PFS difference between LR and TACE to assist in the optimal treatment choice. |
DOI | 10.14309/ctg.0000000000000070 |
关键词[WOS] | RADIOFREQUENCY ABLATION ; SURGICAL RESECTION ; SURVIVAL ; SORAFENIB ; OUTCOMES ; UPDATE |
收录类别 | SCI |
语种 | 英语 |
资助项目 | National Key R&D Program of China[2017YFA0205200] ; National Key R&D Program of China[2017YFC1308700] ; National Key R&D Program of China[2017YFC1308701] ; National Key R&D Program of China[2017YFC1309100] ; National Key R&D Program of China[2016CZYD0001] ; National Natural Science Foundation of China[81571785] ; National Natural Science Foundation of China[81771957] ; National Natural Science Foundation of China[81227901] ; National Natural Science Foundation of China[61231004] ; National Natural Science Foundation of China[81771924] ; National Natural Science Foundation of China[81501616] ; National Natural Science Foundation of China[81671851] ; National Natural Science Foundation of China[81527805] ; National Natural Science Foundation of China[81501549] ; Natural Science Foundation of Guangdong Province, China[2016A030311055] ; Natural Science Foundation of Guangdong Province, China[2016A030313770] ; Science and Technology Service Network Initiative of the Chinese Academy of Sciences[KFJ-SW-STS-160] ; Instrument Developing Project of the Chinese Academy of Sciences[YZ201502] ; Beijing Municipal Science and Technology Commission[Z161100002616022] ; Youth Innovation Promotion Association CAS ; National Key R&D Program of China[2017YFA0205200] ; National Key R&D Program of China[2017YFC1308700] ; National Key R&D Program of China[2017YFC1308701] ; National Key R&D Program of China[2017YFC1309100] ; National Key R&D Program of China[2016CZYD0001] ; National Natural Science Foundation of China[81571785] ; National Natural Science Foundation of China[81771957] ; National Natural Science Foundation of China[81227901] ; National Natural Science Foundation of China[61231004] ; National Natural Science Foundation of China[81771924] ; National Natural Science Foundation of China[81501616] ; National Natural Science Foundation of China[81671851] ; National Natural Science Foundation of China[81527805] ; National Natural Science Foundation of China[81501549] ; Natural Science Foundation of Guangdong Province, China[2016A030311055] ; Natural Science Foundation of Guangdong Province, China[2016A030313770] ; Science and Technology Service Network Initiative of the Chinese Academy of Sciences[KFJ-SW-STS-160] ; Instrument Developing Project of the Chinese Academy of Sciences[YZ201502] ; Beijing Municipal Science and Technology Commission[Z161100002616022] ; Youth Innovation Promotion Association CAS |
项目资助者 | National Key R&D Program of China ; National Natural Science Foundation of China ; Natural Science Foundation of Guangdong Province, China ; Science and Technology Service Network Initiative of the Chinese Academy of Sciences ; Instrument Developing Project of the Chinese Academy of Sciences ; Beijing Municipal Science and Technology Commission ; Youth Innovation Promotion Association CAS |
WOS研究方向 | Gastroenterology & Hepatology |
WOS类目 | Gastroenterology & Hepatology |
WOS记录号 | WOS:000487054100001 |
出版者 | LIPPINCOTT WILLIAMS & WILKINS |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://ir.ia.ac.cn/handle/173211/27005 |
专题 | 中国科学院分子影像重点实验室 |
通讯作者 | Tian, Jie; Lu, Ligong |
作者单位 | 1.Jinan Univ, Zhuhai Intervent Med Ctr, Zhuhai Precis Med Ctr, Zhuhai Peoples Hosp, Zhuhai, Peoples R China 2.Chinese Acad Sci, Key Lab Mol Imaging, Inst Automat, Beijing, Peoples R China 3.Univ Chinese Acad Sci, Beijing, Peoples R China 4.Jinan Univ, Dept Radiol, Zhuhai Peoples Hosp, Zhuhai Hosp, Zhuhai, Peoples R China 5.Southern Med Univ, Dept Biostat, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China 6.Zhongshan City Peoples Hosp, Dept Intervent Treatment, Zhongshan, Peoples R China 7.Shenzhen Peoples Hosp, Dept Radiol, Shenzhen, Peoples R China 8.Southern Med Univ, Intervent Diag & Treatment Dept, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China 9.Yangiang Peoples Hosp, Dept Radiol, Yangjiang, Peoples R China 10.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing, Peoples R China |
推荐引用方式 GB/T 7714 | Fu, Sirui,Wei, Jingwei,Zhang, Jie,et al. Selection Between Liver Resection Versus Transarterial Chemoembolization in Hepatocellular Carcinoma: A Multicenter Study[J]. CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY,2019,10:12. |
APA | Fu, Sirui.,Wei, Jingwei.,Zhang, Jie.,Dong, Di.,Song, Jiangdian.,...&Lu, Ligong.(2019).Selection Between Liver Resection Versus Transarterial Chemoembolization in Hepatocellular Carcinoma: A Multicenter Study.CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY,10,12. |
MLA | Fu, Sirui,et al."Selection Between Liver Resection Versus Transarterial Chemoembolization in Hepatocellular Carcinoma: A Multicenter Study".CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY 10(2019):12. |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论